Combination of Hyaluronic Acid, Chondroitin Sulphate, and Poloxamer 407 for the Prevention and Treatment of Radiation Esophagitis (Results of the RESOXX Multicenter Prospective Observational Study)
Open Access
- 5 September 2026
- journal article
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 45-54
Abstract
Aim: to evaluate the efficacy of an oral medical device — a fixed combination of hyaluronic acid, chondroitin sulphate, and the bioadhesive agent poloxamer 407 (Alfasoxx), on the incidence, course, and severity of radiation esophagitis symptoms in patients undergoing external beam radiotherapy for a primary malignancy. Materials and methods. A total of 215 patients were enrolled in the study, of whom 210 were included in the statistical analysis. Patients were divided into two groups: a treatment group (patients with manifestations of radiation esophagitis at study entry) and a prophylaxis group (patients enrolled on the start date of external beam radiotherapy). Seventeen oncologists from nine Russian cities participated in the study. Assessment methods included clinical and demographic evaluation, analysis of the incidence and distribution of radiation esophagitis risk factors, evaluation of radiation esophagitis severity according to CTCAE v. 5.0, assessment of radiation dose delivered to the esophagus, Alfasoxx dosage accounting for compliance, evaluation of the time to radiation esophagitis onset and its duration, analysis of swallowing function using the EAT-10 questionnaire, assessment of overall health-related quality of life using the EORTC QLQ-C30 questionnaire, and monitoring of adverse events. Results. Manifestations of radiation esophagitis were observed in 68.5 % of patients in the prophylaxis group; therefore, radiation esophagitis did not develop in 31.5 % of patients. Compared with the prophylaxis group, patients in the treatment group experienced a more severe course of the disease, with a mean radiation esophagitis severity score of 0.83 ± 0.53 vs. 0.52 ± 0.25 (p < 0.001). The mean EAT-10 score at baseline differed from that in the treatment group. However, from Visit 2 onward, mean scores aligned and demonstrated identical dynamics. A similar distribution was observed for overall quality of life as assessed by the EORTC QLQ-C30 questionnaire. The significant difference observed at the first visit (68.73 ± 15.69 points in the prophylaxis group vs. 58.24 ± 16.04 points in the treatment group; p < 0.001) was leveled by Visit 4 among patients who developed radiation esophagitis (79.96 ± 10.91 points in the prophylaxis group and 81.25 ± 11.03 points in the treatment group). Only one adverse event was identified during Alfasoxx administration: mild nausea after intake. Conclusion. The prophylactic administration of Alfazox concurrently with the initiation of external beam radiotherapy reduces the mean severity of radiation-induced esophagitis and shortens the duration of symptom manifestation.Keywords
This publication has 11 references indexed in Scilit:
- Factors associated with acute esophagitis during radiation therapy for lung cancerRadiotherapy and Oncology, 2024
- Практические рекомендации по лечению и профилактике мукозитовMalignant tumours, 2021
- Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer TherapiesActas Dermo-Sifiliograficas, 2021
- Radiation‐induced oesophagitis in breast cancer: Factors influencing onset and severity for patients receiving supraclavicular nodal irradiationJournal of Medical Imaging and Radiation Oncology, 2019
- How Efficacious is Ziverel® for Symptomatic Relief of Acute Radiation-Induced Esophagitis? Retrospective Study of Patients Receiving Oncologic TreatmentCancer Therapy & Oncology International Journal, 2017
- Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non‐erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulationAlimentary Pharmacology & Therapeutics, 2017
- Radiation-induced esophagitis in lung cancerLung Cancer: Targets and Therapy, 2016
- Validating and Improving the Reliability of the EORTC QLQ-C30 Using a Multidimensional Rasch ModelValue in Health, 2013
- Validity and Reliability of the Eating Assessment Tool (EAT-10)Annals of Otology, Rhinology & Laryngology, 2008
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995